ClinicalTrials.gg
RecruitingNCT06273436HEAR4MamasUpdated Jul 22, 2026

Healing, Equity, Advocacy and Respect for Mamas

An interventional study of H.E.A.R. for Mamas in Postpartum Complication, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to female participants aged 16 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Primary conditionnone(registry's first term: Emergencies)No conditionIs this wrong?Emergencies describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
2,894
Allocation
Randomized
Ages
16 Years to 49 Years
Sex
Female
01

Study summary

The goal of the proposed research is to test the comparative effectiveness of AIM safety bundles for post-partum women delivered in-person vs. via text/phone to improve early detection of and timely care for complications during the first six weeks postpartum for women experiencing significant health disparities.

Read the detailed description

The purpose of the study is to learn if a program for newborn mom's can improve detection of complications after delivery and help women get medical care quickly and easily. Participants will be asked to complete a survey at the time of enrollment and at 3 additional times. All surveys can be completed via cell-phone or email. All women will be followed for 1-year after delivery. Women that enroll will be assigned to one of two groups: usual in person care OR usual in-person care PLUS a text message-based program that will ask about sign and symptoms of complications that may occur after delivery. If there is a concern, a nurse advocate will call on the phone to discuss options and help refer to care if needed. Participants will be paid for their time in completing surveys.

02

Conditions studied

  • Postpartum Complication

Browse trials for

Keywords

  • AIM (Alliance for Innovation on Maternal Health) safety bundles
  • Randomized Controlled Trial (RCT)
  • Emergency Department (ED) visits
  • Shared Decision Making (SDM)
  • Patient-Reported Outcomes (PROs)
  • Patient Stakeholder Group (PSG)
  • Study Advisory Committee (SAC)
03

In context

Lead sponsor

Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 166 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postpartum woman within approximately 2 weeks of delivering a baby of gestational age ≥ 26 weeks in South Carolina.
  • Aged 16-49 years old.
  • Insured by Medicaid.

Exclusion criteria

Exclusion Criteria for Postpartum Women

  • Plans to relocate outside of SC anytime during the postpartum year.
  • Plans to discontinue Medicaid health insurance during the postpartum year.
  • Speaks a language other than English or Spanish.
  • Incarcerated/pending incarceration during peripartum period.
  • Currently institutionalized.
  • Enrolled in current MUSC study funded by PCORI (#Pro00123833)
  • Does not have and/or does not wish to use their personal cell phone for the study.

Inclusion Criteria for Obstetric Providers and Hospital Administrators

- OB provider working at a delivery hospital in SC and directly involved in the care of postpartum women; or hospital administrator working in a delivery hospital in SC and job responsibilities relate to the postpartum unit.

Exclusion Criteria for Obstetric Providers and Hospital Administrators

  • Less than 1 month of HEAR 4 Mamas experience if involved in the hospital where participants are recruited from.
  • Unable or unwilling to commit to completing surveys or an interview.
  • Speaking a language other than English.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,894 participants (estimated)

Study arms

  • No intervention
    Usual Care

    AIM (AIM Alliance for Innovation on Maternal Health) safety bundles delivered in-person

  • Experimental
    Usual Care plus H.E.A.R. for Mamas

    H.E.A.R. for Mamas is designed to provide the AIM (Alliance for Innovation on Maternal Health) Postpartum Discharge Transition education systematically and to frequently monitor women for signs and symptoms of postpartum complications using simple, patient-centered technology (text/phone).

    Other: H.E.A.R. for Mamas

Interventions

  • OtherH.E.A.R. for Mamas

    H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.

06

What researchers measure

Primary outcomes

  1. Emergency Department (ED) visits within six weeks postpartum

    Percent of postpartum women with an ED visit that occurs within six weeks following delivery

    Time frame: Within six weeks following the delivery

Secondary outcomes

  1. Patient Reported Outcomes (PROs)

    Secondary outcomes will include PROs which will be measured at the time of study enrollment (baseline=0), and 3, 6, and 12 months postpartum.

    Time frame: time of study enrollment (baseline=0), and 3, 6, and 12 months postpartum

Other outcomes

  1. Social Determinants of Health (SDoH), Patient Activation, Shared Decision Making

    SDoH will be measured by the Accountable Health Communities-Health-Related Social Needs (HRSN) and includes assessment of economic instability, low social support, food scarcity etc.

    Time frame: HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum

  2. Patient Activation

    Patient activation will be measured by the Patient Activation Measure (PAM-10).

    Time frame: HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum

  3. Shared Decision Making

    Perception of the shared decision-making process will be measured by Shared Decision-Making Questionnaire (SDM-Q-9).

    Time frame: HRSN, PAM-10, and SDM-Q-9 will be measured at study enrollment (baseline=0), 3, 6, and 12 months postpartum

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06273436
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Constance Guille (Professor - Faculty, Medical University of South Carolina) — Principal investigator
First posted
Feb 22, 2024
Start date
May 28, 2024
Primary completion
Nov 30, 2028 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Jul 22, 2026

Study contacts

Constance Guille, MD
Contact
guille@musc.edu
843-792-6489
Edie Douglas
Contact
douglaed@musc.edu
8439985635

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion